Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza a virus

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Hoopes, Justin D ^a   Driebe, Elizabeth M ^b   Kelley, Erin ^b   Engelthaler, David M ^b   Keim, Paul S ^b   Perelson, Alan S ^c   Rong, Libin ^d   Went, Gregory T ^a   Nguyen, Jack T ^a  

^a Adamas Pharmaceuticals Inc   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c LOS ALAMOS NATIONAL LABORATORY   (United States)

^d OAKLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; OSELTAMIVIR; RIBAVIRIN; ANTIVIRUS AGENT;

ANIMAL CELL; ANTIVIRAL RESISTANCE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG COMBINATION; DRUG SELECTIVITY; EXPERIMENTAL STUDY; GENE MUTATION; IN VITRO STUDY; INFLUENZA VIRUS A; MATHEMATICAL MODEL; NONHUMAN; NUCLEOTIDE SEQUENCE; VIRUS CULTURE; VIRUS INHIBITION; AMINO ACID SUBSTITUTION; ANIMAL; CELL LINE; DOG; DOSE RESPONSE; DRUG EFFECT; GENE REPRESSION; GENETICS; GENOTYPE; PHENOTYPE;

INFLUENZA A VIRUS;

AMANTADINE; AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; INFLUENZA A VIRUS; OSELTAMIVIR; PHENOTYPE; RIBAVIRIN; SERIAL PASSAGE; SUPPRESSION, GENETIC;

EID: 84855261948     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029778     Document Type: Article

References (43)

1. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, et al. (2010) Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304: 321-333.
2. Daar ES, Richman DD, (2005) Confronting the emergence of drug-resistant HIV type 1: impact of antiretroviral therapy on individual and population resistance. AIDS Res Hum Retroviruses 21: 343-357.
3. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, et al. (2006) The survival benefits of AIDS treatment in the United States. J Infect Dis 194: 11-19.
4. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337: 734-739.
5. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, et al. (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 337: 725-733.
6. Monto A, Schooley RT, Lai JC, Sulkowski MS, Chung RT, et al. (2010) Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop. Am J Gastroenterol 105: 989-1004.
7. Centers for Disease Control and Prevention (2010b) Update: influenza activity- United States, 2009-10 season. MMWR Morb Mortal Wkly Rep 59: 901-908.
8. Centers for Disease Control and Prevention (2009) Update: influenza activity-United States, September 28, 2008-April 4, 2009, and composition of the 2009-10 influenza vaccine. MMWR Morb Mortal Wkly Rep 58: 369-374.
9. Centers for Disease Control and Prevention (2009) Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 58: 433-435.
10. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG, (2009) Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 83: 10366-10373.
11. McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, Tiong T, Marshall D, et al. (1996) Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother 40: 40-46.
12. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, McDonald M, Colman PM, et al. (1998) Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 72: 2456-2462.
13. Mishin VP, Hayden FG, Gubareva LV, (2005) Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 49: 4515-4520.
14. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353: 2667-2672.
15. Centers for Disease Control and Prevention (2009) Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina, 2009. MMWR Morb Mortal Wkly Rep 58: 969-972.
16. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O, (2009) Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 15: 155-162.
17. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, et al. (2008) Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 52: 3284-3292.
18. Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, Sheu TG, Xu X, et al. (2010) Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother 54: 1834-1841.
19. van der Vries E, Stelma FF, Boucher CA, (2010) Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 363: 1381-1382.
20. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV, (2010) Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis 51: 983-984.
21. Nguyen JT, Hoopes JD, Le MH, Smee DF, Patick AK, et al. (2010) Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 5: e9332.
22. Nguyen JT, Hoopes JD, Smee DF, Prichard MN, Driebe EM, et al. (2009) Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 53: 4115-4126.
23. Perelson AS, Essunger P, Ho DD, (1997) Dynamics of HIV-1 and CD4+ lymphocytes in vivo. AIDS 11 (Suppl A): S17-24.
24. Parvin JD, Moscona A, Pan WT, Leider JM, Palese P, (1986) Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1. J Virol 59: 377-383.
25. Sanjuan R, Nebot MR, Chirico N, Mansky LM, Belshaw R, (2010) Viral mutation rates. J Virol 84: 9733-9748.
26. Laohpongspaisan C, Rungrotmongkol T, Intharathep P, Malaisree M, Decha P, et al. (2009) Why amantadine loses its function in influenza m2 mutants: MD simulations. J Chem Inf Model 49: 847-852.
27. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA, (2006) Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 70: 121-131.
28. Ison MG, Gnann JW Jr, Nagy-Agren S, Treannor J, Paya C, et al. (2003) Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 8: 183-190.
29. Jordan R, Gold L, Cummins C, Hyde C, (2002) Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ 324: 757.
30. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, et al. (1998) Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. Jama 280: 35-41.
31. Markowitz M, Vesanen M, Tenner-Racz K, Cao Y, Binley JM, et al. (1999) The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 179: 527-537.
32. Dybul MFAS, Bartlett JG, Kaplan JE, Pau AK, (2002) Guidelines for Using Antiretroviral Agents Among HIV-Infected Adults and Adolescents. MMWR Recommendations and Reports 51: 1.
33. Abed Y, Goyette N, Boivin G, (2005) Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrob Agents Chemother 49: 556-559.
34. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD, (2003) Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 77: 8418-8425.
35. Abed Y, Bourgault AM, Fenton RJ, Morley PJ, Gower D, et al. (2002) Characterization of 2 influenza A(H3N2) clinical isolates with reduced susceptibility to neuraminidase inhibitors due to mutations in the hemagglutinin gene. J Infect Dis 186: 1074-1080.
36. Freistadt MS, Meades GD, Cameron CE, (2004) Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? Drug Resist Updat 7: 19-24.
37. Ward CL, Dev A, Rigby S, Symonds WT, Patel K, et al. (2008) Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase. J Viral Hepat.
38. Nobusawa E, Sato K, (2006) Comparison of the mutation rates of human influenza A and B viruses. J Virol 80: 3675-3678.
39. Baccam P, Beauchemin C, Macken CA, Hayden FG, Perelson AS, (2006) Kinetics of influenza A virus infection in humans. J Virol 80: 7590-7599.
40. Saenz RA, Quinlivan M, Elton D, Macrae S, Blunden AS, et al. (2010) Dynamics of influenza virus infection and pathology. J Virol 84: 3974-3983.
41. Mohler L, Flockerzi D, Sann H, Reichl U, (2005) Mathematical model of influenza A virus production in large-scale microcarrier culture. Biotechnol Bioeng 90: 46-58.
42. Nobusawa E, Aoyama T, Kato H, Suzuki Y, Tateno Y, et al. (1991) Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. Virology 182: 475-485.
43. Liu CM, Driebe EM, Schupp J, Kelley E, Nguyen JT, et al. (2010) Rapid quantification of single-nucleotide mutations in mixed influenza A viral populations using allele-specific mixture analysis. J Virol Methods 163: 109-115.